Antibiotice SA 2011 Annual Report with Sustainability Disclosures
The report highlights Antibiotic SA's performance and strategic development in 2011. The company achieved a 16% increase in net turnover to RON 281.8 million and a 62% increase in net profit to RON 20.3 million. Key achievements include the modernization of its tablet manufacturing line, the launch of a new Central Nervous System therapeutic class, and obtaining FDA approval for its Nafcillin powder for injection. Additionally, the company continued its social and environmental initiatives through the 'Antibiotice - Science and Soul' Foundation and the 'Be Pro Nature. Get Involved!' program.
Company: Antibiotice SA
Sector: Manufacturing
Country: Romania
Year: 2011
Type: Annual Report with Sustainability Disclosures
Pages: 82
Back to company
Antibiotice SA
Annual Report
The report highlights Antibiotic SA's performance and strategic development in 2011. The company achieved a 16% increase in net turnover to RON 281.8 million and a 62% increase in net profit to RON 20.3 million. Key achievements include the modernization of its tablet manufacturing line, the launch of a new Central Nervous System therapeutic class, and obtaining FDA approval for its Nafcillin powder for injection. Additionally, the company continued its social and environmental initiatives through the 'Antibiotice - Science and Soul' Foundation and the 'Be Pro Nature. Get Involved!' program.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2011
Reporting Period
Jan 1, 2011 - Dec 31, 2011
Fiscal Year
2011
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Employees